COVID-19 in patients with end stage kidney disease at a large community hospital in Eastern Saudi Arabia. A prospective study

References

1. 1.↵
   1. Xiong F,
   2. Tang H,
   3. Liu L,
   4. Tu C,
   5. Tian JB,
   6. Lei CT, et al.

   Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China. J Am Soc Nephrol 2020; 31: 1387-1397.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Valeri AM,
   2. Robbins-Juarez SY,
   3. Stevens JS,
   4. Ahn W,
   5. Rao MK,
   6. Radhakrishnan J, et al.

   Presentation and Outcomes of Patients with ESKD and COVID-19. J Am Soc Nephrol 2020; 31: 1409-1415.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Goicoechea M,
   2. Sánchez Cámara LA,
   3. Macías N,
   4. Muñoz de Morales A,
   5. Rojas Á G,
   6. Bascuñana A, et al.

   COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney Int 2020; 98: 27-34.

   OpenUrlPubMed
4. 4.↵
   1. La Milia V,
   2. Bacchini G,
   3. Bigi MC,
   4. Casartelli D,
   5. Cavalli A,
   6. Corti M, et al.

   COVID-19 outbreak in a large hemodialysis center in Lombardy, Italy. Kidney Int Rep 2020; 5: 1095-1099.

   OpenUrl
5. 5.↵
   1. Go AS,
   2. Chertow GM,
   3. Fan D,
   4. McCulloch CE

   , Hsu C-y. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Engl J Med 2004; 351: 1296-1305.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Williamson EJ,
   2. Walker AJ,
   3. Bhaskaran K,
   4. Bacon S,
   5. Bates C,
   6. Morton CE, et al.

   Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-436.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Hobbs ALV,
   2. Turner N,
   3. Omer I,
   4. Walker MK,
   5. Beaulieu RM,
   6. Sheikh M, et al.

   Risk factors for mortality and progression to severe COVID-19 disease in the Southeast United States (US): A Report from the SEUS Study Group. Infect Control Hosp Epidemiol 2021; 42: 1464-1472.

   OpenUrl
8. 8.↵
   1. Hilbrands LB,
   2. Duivenvoorden R,
   3. Vart P,
   4. Franssen CFM,
   5. Hemmelder MH,
   6. Jager KJ, et al.

   COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant 2020; 35: 1973-1983.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Chan L,
   2. Jaladanki SK,
   3. Somani S,
   4. Paranjpe I,
   5. Kumar A,
   6. Zhao S, et al.

   Outcomes of Patients on Maintenance Dialysis Hospitalized with COVID-19. Clin J Am Soc Nephrol 2021; 16: 452-455.

   OpenUrlFREE Full Text
10. 10.↵
    1. Ng JH,
    2. Hirsch JS,
    3. Wanchoo R,
    4. Sachdeva M,
    5. Sakhiya V,
    6. Hong S, et al.

    Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int 2020; 98: 1530-1539.

    OpenUrlPubMed
11. 11.↵
    Ministry of Health. Dashboard hcmgsMSAC-. [Updated 2022; Accessed 2022 Jan 5]. Available from: https://covid19.moh.gov.sa/
12. 12.↵
    1. Horby P,
    2. Lim WS,
    3. Emberson JR,
    4. Mafham M,
    5. Bell JL,
    6. Linsell L, et al.

    Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693-704.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Salama C,
    2. Han J,
    3. Yau L,
    4. Reiss WG,
    5. Kramer B,
    6. Neidhart JD, et al.

    Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021; 384: 20-30.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Tang Y,
    2. Liu J,
    3. Zhang D,
    4. Xu Z,
    5. Ji J,
    6. Wen C.

    Cytokine Storm in COVID-19: The current evidence and treatment strategies. Front Immunol 2020; 11: 1708.

    OpenUrlPubMed
15. 15.↵
    1. Kato S,
    2. Chmielewski M,
    3. Honda H,
    4. Pecoits-Filho R,
    5. Matsuo S,
    6. Yuzawa Y, et al.

    Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526-1533.

    OpenUrlAbstract/FREE Full Text